Dyax Corp. (DYAX) and CVie Therapeutics Announce Partnership to Develop and Commercialize KALBITOR® (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in China, Hong Kong and Macau
2/7/2013 9:54:57 AM
BURLINGTON, Mass. & HONG KONG--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, and CVie Therapeutics (CVie), a subsidiary of Lee’s Pharmaceutical Holdings Ltd., announced today a strategic partnership for the development and commercialization of KALBITOR® (ecallantide) in the treatment of hereditary angioedema (HAE) and other angioedema indications in China, Hong Kong and Macau. KALBITOR is currently marketed in United States for the treatment of acute attacks of HAE in patients 16 years of age and older. Under the terms of the exclusive license agreement, Dyax will receive an upfront payment and is eligible to receive future development, regulatory and sales milestones. Dyax is also eligible to receive royalty on net product sales. CVie is solely responsible for all costs associated with development, regulatory activities, and the commercialization of KALBITOR in China, Hong Kong and Macau. Additionally, CVie will purchase drug product from Dyax on a cost-plus basis for commercial supply.